With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
The large phase 3 DETERMINATION trial has cemented lenalidomide, bortezomib, and dexamethasone (RVd) with stem cell mobilization followed by lenalidomide until progression as the standard of care for newly-diagnosed multiple myeloma. | ASCO 2022
Comments
Post a Comment